Form 4: Quest Diagnostics Director Reports Early Dividend Reinvestment Share Acquisition

A director at Quest Diagnostics Inc. has reported the acquisition of 79 shares of common stock through a dividend reinvestment plan, with the transaction dated for July 21, 2025, and filed early.

Summary

• Vicky B. Gregg, a Director of Quest Diagnostics Inc. (DGX), reported a transaction involving the company's common stock.
• The transaction occurred on July 21, 2025, and was filed on July 25, 2025.
• Gregg acquired 79 shares of common stock at a price of $167.495 per share.
• The acquisition was made pursuant to a dividend reinvestment plan administered by the reporting person's broker.
• This transaction was eligible for deferred reporting on Form 5 under Rule 16a-6, but the reporting person chose to report it early on Form 4.
• Following this transaction, Vicky B. Gregg directly beneficially owns 18,217 shares of Quest Diagnostics Inc. common stock.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While a routine transaction, a director's continued participation in a dividend reinvestment plan and early reporting are generally viewed favorably as a sign of ongoing commitment, though the transaction size is small.

Positives

• The acquisition of shares through a dividend reinvestment plan indicates a continued investment in the company by a director.
• The early reporting of the transaction, though not legally required until Form 5, demonstrates transparency.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance beyond the future transaction date.

Industry Context

This specific insider transaction, involving a relatively small number of shares acquired through a dividend reinvestment plan, is a routine disclosure and does not typically reflect broader industry trends or competitive dynamics within the diagnostics sector.

Stakeholder Impact

• Shareholders: The transaction indicates a director's continued investment in the company, which can be seen as a positive signal of alignment with shareholder interests.

Key Dates

Recommendation

This Form 4 filing reports a routine acquisition of shares through a dividend reinvestment plan by a director. The transaction size is small relative to the company's market capitalization and the director's total holdings. It does not provide new material information that would significantly alter the investment thesis for Quest Diagnostics Inc., thus a 'hold' recommendation is appropriate as it confirms ongoing, stable insider investment without indicating a major shift in outlook.

Keywords

Quest Diagnostics, DGX, SEC Form 4, Insider Trading, Director, Share Acquisition, Dividend Reinvestment Plan, Rule 10b5-1(c)